Shlomo Melmed Selected Research

Growth Hormone (Somatotropin)

1/2022	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.
1/2022	Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
11/2021	International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly.
8/2021	Insulin-like Growth Factor 1 and Prolactin Levels in Chimpanzees (Pan troglodytes) Across the Lifespan.
11/2020	DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas.
10/2019	Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study.
1/2019	Acromegaly.
2/2017	Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.
1/2017	Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
6/2016	Growth hormone is permissive for neoplastic colon growth.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shlomo Melmed Research Topics

Disease

62	Neoplasms (Cancer) 01/2022 - 01/2000
55	Pituitary Neoplasms (Pituitary Adenoma) 01/2022 - 01/2000
39	Acromegaly 01/2022 - 01/2002
21	Adenoma (Adenomas) 11/2022 - 01/2000
12	Pituitary ACTH Hypersecretion 01/2022 - 11/2002
11	Prolactinoma (Prolactinomas) 01/2021 - 02/2003
10	Carcinogenesis 01/2022 - 01/2002
9	Growth Hormone-Secreting Pituitary Adenoma 01/2022 - 01/2000
6	Hyperplasia 10/2012 - 01/2002
5	ACTH-Secreting Pituitary Adenoma 01/2021 - 11/2002
4	Cushing Syndrome 09/2018 - 05/2011
3	Ataxia Telangiectasia (Louis Bar Syndrome) 02/2019 - 12/2012
3	Inflammation (Inflammations) 01/2019 - 05/2002
3	Carcinoid Tumor (Carcinoid) 09/2018 - 12/2007
3	Body Weight (Weight, Body) 02/2017 - 08/2008
2	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2003
2	Carcinoma (Carcinomatosis) 01/2021 - 05/2009
2	Injection Site Reaction 02/2016 - 09/2008
2	Hypogonadism (Hypergonadotropic Hypogonadism) 06/2015 - 08/2014
2	Chromosomal Instability (Chromosome Stability) 08/2013 - 12/2012
2	Hyperprolactinemia 02/2011 - 07/2006
2	Colonic Neoplasms (Colon Cancer) 01/2011 - 03/2008
2	Pituitary Diseases (Disease, Anterior Pituitary) 03/2010 - 02/2008
2	Aneuploidy (Aneuploid) 11/2008 - 11/2003
2	Headache (Headaches) 09/2008 - 07/2006
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 05/2008 - 12/2007
2	Hypopituitarism (Sheehan's Syndrome) 10/2003 - 05/2003
1	Fibrosis (Cirrhosis) 01/2022
1	Delayed Puberty 08/2021
1	Bradycardia 01/2021
1	Exanthema (Rash) 01/2021

Drug/Important Bio-Agent (IBA)

31	Growth Hormone (Somatotropin)IBA 01/2022 - 01/2000
22	Insulin-Like Growth Factor I (IGF-1)IBA 01/2022 - 01/2002
20	Hormones (Hormone)IBA 11/2022 - 05/2003
18	LigandsIBA 01/2022 - 05/2003
18	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2021 - 05/2002
18	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 02/2017 - 01/2000
14	ProlactinIBA 01/2015 - 01/2002
13	Octreotide (Sandostatin)FDA LinkGeneric 01/2022 - 01/2000
13	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2022 - 06/2004
12	Messenger RNA (mRNA)IBA 01/2022 - 01/2000
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2003
9	SecurinIBA 12/2012 - 03/2003
8	lanreotide (Somatuline)FDA Link 01/2022 - 01/2002
7	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 01/2021 - 05/2011
7	Pharmaceutical PreparationsIBA 07/2015 - 10/2003
6	Dopamine Agonists (Dopamine Agonist)IBA 01/2021 - 10/2003
6	Insulin (Novolin)FDA Link 10/2019 - 10/2006
5	Insulin-Like PeptidesIBA 01/2022 - 03/2008
5	Tyrosine Kinase InhibitorsIBA 01/2021 - 10/2011
5	Hydrocortisone (Cortisol)FDA LinkGeneric 09/2018 - 08/2014
5	pasireotideIBA 02/2017 - 06/2004
5	ErbB Receptors (EGF Receptor)IBA 02/2017 - 01/2006
5	Estrogens (Estrogen)FDA Link 10/2012 - 01/2002
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2003
4	pegvisomant FDA LinkGeneric 01/2020 - 01/2002
4	CorticosteroneIBA 02/2017 - 11/2002
4	Dopamine (Intropin)FDA LinkGeneric 02/2017 - 11/2003
4	Transcription Factors (Transcription Factor)IBA 06/2016 - 04/2010
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2015 - 10/2005
4	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 04/2014 - 04/2003
4	CytokinesIBA 03/2009 - 05/2002
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2006
3	Lapatinib (GW572016)FDA Link 01/2021 - 01/2011
3	Phosphotransferases (Kinase)IBA 02/2019 - 12/2012
3	Gefitinib (Iressa)FDA Link 02/2017 - 08/2008
3	GlucocorticoidsIBA 07/2015 - 11/2002
3	somatostatin receptor 2IBA 01/2015 - 06/2004
3	Epidermal Growth Factor (EGF)IBA 04/2014 - 08/2008
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2008 - 10/2003
3	Leukemia Inhibitory FactorIBA 03/2006 - 05/2002
3	PlasticsIBA 03/2006 - 12/2003
2	RoscovitineIBA 07/2015 - 05/2011
2	Cyclin EIBA 07/2015 - 05/2011
2	ClusterinIBA 12/2012 - 03/2011
2	TBR-760IBA 10/2012 - 12/2007
2	Biological ProductsIBA 09/2012 - 11/2005
2	Glucose (Dextrose)FDA LinkGeneric 12/2011 - 02/2009
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 05/2011 - 02/2006
2	Luteinizing Hormone (Lutropin)FDA LinkGeneric 05/2011 - 05/2003
2	Follicle Stimulating Hormone (Follitropin)FDA Link 05/2011 - 04/2008
2	SteroidsIBA 01/2010 - 09/2008
2	aryl hydrocarbon receptor-interacting proteinIBA 05/2007 - 12/2006
2	enhanced green fluorescent proteinIBA 10/2006 - 11/2003
2	Glycoproteins (Glycoprotein)IBA 10/2006 - 05/2005
2	Rosiglitazone (Avandia)FDA Link 05/2003 - 11/2002
2	PPAR gammaIBA 05/2003 - 11/2002
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 05/2003 - 11/2002
2	ThiazolidinedionesIBA 05/2003 - 11/2002
1	Mitogen-Activated Protein KinasesIBA 01/2022
1	OsilodrostatIBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	Actin Depolymerizing Factors (Cofilins)IBA 01/2022
1	4-O-carboxymethylascochlorinIBA 01/2021
1	Growth Factor ReceptorsIBA 01/2021

Therapy/Procedure

34	Therapeutics 11/2022 - 01/2000
5	Drug Therapy (Chemotherapy) 05/2011 - 03/2003
4	Injections 01/2022 - 05/2008
4	Radiotherapy 12/2021 - 07/2005
2	Subcutaneous Injections 05/2003 - 11/2002